358 related articles for article (PubMed ID: 25162417)
1. A critical role for the mTORC2 pathway in lung fibrosis.
Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
[TBL] [Abstract][Full Text] [Related]
2. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
3. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.
Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB
Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990
[TBL] [Abstract][Full Text] [Related]
4. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
5. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
[TBL] [Abstract][Full Text] [Related]
6. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
7. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
9. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
10. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
12. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis.
Li J; Ren J; Liu X; Jiang L; He W; Yuan W; Yang J; Dai C
Kidney Int; 2015 Sep; 88(3):515-27. PubMed ID: 25970154
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
14. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
[TBL] [Abstract][Full Text] [Related]
15. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
18. TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation.
O'Leary EM; Tian Y; Nigdelioglu R; Witt LJ; Cetin-Atalay R; Meliton AY; Woods PS; Kimmig LM; Sun KA; Gökalp GA; Mutlu GM; Hamanaka RB
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):601-612. PubMed ID: 32668192
[TBL] [Abstract][Full Text] [Related]
19. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
20. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.
Morrison MM; Young CD; Wang S; Sobolik T; Sanchez VM; Hicks DJ; Cook RS; Brantley-Sieders DM
PLoS Genet; 2015 Jul; 11(7):e1005291. PubMed ID: 26132202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]